Table 2.
Comparison of patient and disease characteristics stratified by primary site
| Characteristic | Hypopharynx (N=1,085) | Larynx (N=4,804) | Oral Cavity (N=4,018) | Oropharynx (N=14,833) |
|---|---|---|---|---|
| Median Age at Diagnosis (SD) | 61 (10.48) | 62 (11.4) | 60 (13.53) | 58 (9.55) |
| Median Length of follow-up | 2.3 | 2.5 | 2.5 | 2.7 |
| HPV Data Available (non-missing HPV status/all patients queried) | 12.9% (2,921/22,705) | 9.7% (10,210/105,593) | 11.5% (8,972/78,034) | 24.6% (29,409/119,393) |
| HPV Status | ||||
| Positive | 192 (17.7%) | 530 (11%) | 426 (10.6%) | 9332 (62.9%) |
| Negative | 893 (82.3%) | 4274 (89%) | 3592 (89.4%) | 5501 (37.1%) |
| Sex | ||||
| Male | 884 (81.5%) | 3716 (77.4%) | 2448 (60.9%) | 12325 (83.1%) |
| Female | 201 (18.5%) | 1088 (22.6%) | 1570 (39.1%) | 2508 (16.9%) |
| Charlson-Deyo Score | ||||
| 0 | 795 (73.3%) | 3415 (71.1%) | 3099 (77.1%) | 12359 (83.3%) |
| 1+ | 290 (26.7%) | 1389 (28.9%) | 919 (22.9%) | 2474 (16.7%) |
| Year of Diagnosis | ||||
| 2010 | 109 (10%) | 539 (11.2%) | 528 (13.1%) | 2085 (14.1%) |
| 2011 | 268 (24.7%) | 1105 (23%) | 939 (23.4%) | 3329 (22.4%) |
| 2012 | 315 (29%) | 1490 (31%) | 1220 (30.4%) | 4317 (29.1%) |
| 2013 | 393 (36.2%) | 1670 (34.8%) | 1331 (33.1%) | 5102 (34.4%) |
| Clinical Group Stage | ||||
| I | 60 (5.5%) | 1402 (29.2%) | 1232 (30.7%) | 607 (4.1%) |
| II | 105 (9.7%) | 769 (16%) | 833 (20.7%) | 1123 (7.6%) |
| III | 223 (20.6%) | 1085 (22.6%) | 498 (12.4%) | 2910 (19.6%) |
| IV | 28 (2.6%) | 68 (1.4%) | 77 (1.9%) | 361 (2.4%) |
| IVA | 555 (51.2%) | 1365 (28.4%) | 1266 (31.5%) | 8853 (59.7%) |
| IVB | 113 (10.4%) | 114 (2.4%) | 110 (2.7%) | 966 (6.5%) |
| Grade | ||||
| Well Differentiated | 38 (4.6%) | 567 (14.7%) | 857 (23.3%) | 457 (4.1%) |
| Moderately Diff. | 442 (53.8%) | 2382 (61.8%) | 2194 (59.7%) | 4814 (42.9%) |
| Poorly Diff. | 342 (41.6%) | 903 (23.4) | 627 (17%) | 5946 (53%) |
| Surgery at Primary Site | ||||
| Yes | 267 (24.6%) | 1787 (37.3%) | 3530 (87.9%) | 5847 (39.4%) |
| No | 817 (75.4%) | 3008 (62.7%) | 488 (12.1%) | 8979 (60.6%) |
| Radiation Therapy | ||||
| Yes | 914 (84.6%) | 3767 (78.9%) | 1987 (49.7%) | 13040 (88.2%) |
| No | 166 (15.4%) | 1010 (21.1%) | 2010 (50.3%) | 1744 (11.8%) |
| Chemotherapy | ||||
| Yes | 785 (73.7%) | 2063 (44%) | 1157 (29.6%) | 11148 (76.4%) |
| No | 280 (26.3%) | 2623 (56%) | 2747 (70.4%) | 3453 (23.6%) |
| Race | ||||
| White | 890 (82%) | 3927 (81.7%) | 3524 (87.7%) | 13412 (90.4%) |
| Black | 166 (15.3%) | 701 (14.6%) | 282 (7%) | 1020 (6.9%) |
| Other/Unknown | 29 (2.7%) | 176 (3.7%) | 212 (5.3%) | 401 (2.7%) |
| Median Income | ||||
| Unknown | 25 | 133 | 118 | 526 |
| <30,000 | 184 (17.4%) | 813 (17.4%) | 517 (13.3%) | 1584 (11.1%) |
| 30,000–35,999 | 197 (18.6%) | 996 (21.3%) | 710 (18.2%) | 2330 (16.3%) |
| 36,000–45,999 | 296 (27.9%) | 1325 (28.4%) | 1091 (28%) | 3918 (27.4%) |
| 46,000+ | 383 (36.1%) | 1537 (32.9%) | 1582 (40.6%) | 6475 (45.3%) |
| Insurance Status | ||||
| Not insured/Unknown | 86 (7.9%) | 413 (8.6%) | 297 (7.4%) | 1012 (6.8%) |
| Private | 376 (34.7%) | 1644 (34.2%) | 1702 (42.4%) | 8424 (56.8%) |
| Medicaid/Medicare/Other Gov’t | 623 (57.4%) | 2747 (57.2%) | 2019 (50.2%) | 5397 (36.4%) |
| Facility Type | ||||
| Community Cancer Program | 194 (18%) | 923 (19.6%) | 574 (15.1%) | 2618 (17.9%) |
| Comprehensive Community Cancer Program | 388 (36.1%) | 1694 (36%) | 994 (26.2%) | 4687 (32.1%) |
| Academic/Research Program | 493 (45.9%) | 2091 (44.4%) | 2225 (58.7%) | 7295 (50%) |
| Integrated Network Cancer Program | ||||
| Facility Location | ||||
| Northeast | 267 (24.8%) | 1150 (24.4%) | 825 (21.8%) | 3101 (21.2%) |
| South | 424 (39.4%) | 1843 (39.1%) | 1359 (35.8%) | 5174 (35.4%) |
| Midwest | 231 (21.5%) | 1110 (23.4%) | 983 (25.9%) | 3772 (25.8%) |
| West | 153 (14.2%) | 615 (13.1%) | 626 (16.5%) | 2553 (17.5%) |